Within 1 day
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Serum or plasma
Red-top tube or green-top (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.
Transfer separated serum or plasma to a plastic transport tube. Peak: 4 to 12 hours after dose; trough: immediately prior to next dose.
Gel-barrier tube; hemolysis; severe lipemia; icteric specimen
Phenobarbital, a long-acting barbiturate, is effective in generalized tonic-clonic and simple partial seizures. Higher plasma concentrations may be required to control the latter. Complex partial seizures do not respond as well, and absence seizures are not relieved and may be exacerbated. Phenobarbital frequently is used in the treatment of neonatal seizures and may be the initial drug employed in young children; however, because of increasing concern about adverse neuropsychological reactions to sedative/hypnotic antiepileptic drugs, many neurologists prefer less sedating drugs, such as carbamazepine, phenytoin, or valproate. The prophylactic use of phenobarbital in infants with febrile seizures has been challenged. Phenobarbital also is useful in seizures caused by barbiturate withdrawal in dependent individuals. The sodium salt is administered parenterally as part of the treatment regimen for status epilepticus.
Therapeutic: 15−40 μg/mL
Phenobarbital has a half-life of 84 to 108 hours. Phenobarbital can affect the metabolism of phenytoin, ethosuximide, and increase the clearance and elimination of chloramphenicol, theophylline, oral anticoagulants (warfarin), cyclosporine, and oral contraceptives; where appropriate, the use of these drugs in patients on phenobarbital should be monitored clinically and through the laboratory.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|007823||Phenobarbital, Serum||3948-7||007828||Phenobarbital, Serum||ug/mL||3948-7|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf